
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Management of hepatocellular carcinoma prior to liver transplantation: latest developments - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15251EB78AEF4193051EB700353B936F.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="heponc">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377145/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Hepatic Oncology">
<meta name="citation_title" content="Management of hepatocellular carcinoma prior to liver transplantation: latest developments">
<meta name="citation_author" content="Antoine Robert">
<meta name="citation_author_institution" content="Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA">
<meta name="citation_author" content="Thomas M Hunold">
<meta name="citation_author_institution" content="Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA">
<meta name="citation_author" content="Neehar D Parikh">
<meta name="citation_author_institution" content="Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA">
<meta name="citation_publication_date" content="2025 Aug 23">
<meta name="citation_volume" content="12">
<meta name="citation_issue" content="1">
<meta name="citation_firstpage" content="2549676">
<meta name="citation_doi" content="10.1080/20450923.2025.2549676">
<meta name="citation_pmid" content="40847915">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377145/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377145/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377145/pdf/IHEP_12_2549676.pdf">
<meta name="description" content="Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding ...">
<meta name="og:title" content="Management of hepatocellular carcinoma prior to liver transplantation: latest developments">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377145/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12377145">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1080/20450923.2025.2549676"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/IHEP_12_2549676.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12377145%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12377145/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12377145/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377145/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-heponc.png" alt="Hepatic Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Hepatic Oncology" title="Link to Hepatic Oncology" shape="default" href="https://doi.org/10.1080/20450923.2025.2549676" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Hepat Oncol</button></div>. 2025 Aug 23;12(1):2549676. doi: <a href="https://doi.org/10.1080/20450923.2025.2549676" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1080/20450923.2025.2549676</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Hepat%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hepat%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Hepat%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Hepat%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Management of hepatocellular carcinoma prior to liver transplantation: latest developments</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Robert%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Antoine Robert</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Antoine Robert</span></h3>
<div class="p">
<sup>1</sup>Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Robert%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Antoine Robert</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hunold%20TM%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Thomas M Hunold</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Thomas M Hunold</span></h3>
<div class="p">
<sup>1</sup>Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hunold%20TM%22%5BAuthor%5D" class="usa-link"><span class="name western">Thomas M Hunold</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Parikh%20ND%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Neehar D Parikh</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Neehar D Parikh</span></h3>
<div class="p">
<sup>1</sup>Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Parikh%20ND%22%5BAuthor%5D" class="usa-link"><span class="name western">Neehar D Parikh</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="AF0001">
<sup>1</sup>Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA</div>
<div class="author-notes p"><div class="fn" id="AN0001">
<sup>✉</sup><p class="display-inline"><strong>CONTACT</strong> Neehar D. Parikh <span>ndparikh@med.umich.edu</span>
Division of Gastroenterology and Hepatology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI, USA.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 11; Accepted 2025 Aug 15; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group</div>
<p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc/4.0/</a>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12377145  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40847915/" class="usa-link">40847915</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding 75%. Current allocation policy in the US restricts transplant to patients with early HCC, and priority for transplant is granted after 6 months on the waitlist, thus patients often require therapies for cancer control while awaiting liver transplantation. The most commonly applied therapies for HCC in patients awaiting liver transplantation are locoregional therapies, including ablative, radiation, and arterial based therapies. Using these therapies patient can be effectively bridged or downstaged to liver transplantation, however there are risks of progressive liver decompensation with locoregional therapies in patients with portal hypertension. There are emerging data for the use of immune checkpoint inhibitor-based immunotherapies in the treatment of HCC. While there has been concern for rejection with the administration of immunotherapy prior to liver transplantation, early data suggest that the risk can be minimized with sufficient washout time prior to liver transplantation. Herein we aim to review management strategies for patients with HCC awaiting liver transplantation.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Hepatocellular carcinoma, liver transplantation, downstage, milan, transarterial chemoembolization, transarterial radioembolization</p></section></section><section class="abstract" id="abstract2"><h2>PLAIN LANGUAGE SUMMARY</h2>
<p>Primary liver cancer is one of the major indications for considering liver transplantation. In this review, we outline the patients who can be selected for liver transplant and strategies to effectively keep patients on the waitlist while they are awaiting a liver transplant.</p></section><section class="abstract" id="abstract3"><h2>ARTICLE HIGHLIGHTS</h2>
<ul class="list" style="list-style-type:disc">
<li><p>Liver transplant is an effective treatment of hepatocellular carcinoma in eligible patients</p></li>
<li><p>Candidacy for liver transplant is most commonly guided by the Milan criteria, however alternate criteria with more permissive tumor burden exist, with acceptable post-liver transplantation results</p></li>
<li><p>Downstaging patients beyond Milan criteria using locoregional or systemic therapies prior to liver transplantation is an effective strategy</p></li>
<li><p>Maintaining patients within transplant criteria using locoregional therapies can be an effective strategy for bridging patients to transplant</p></li>
<li><p>Early data on immunotherapy based regimens prior to liver transplantation for hepatocellular carcinoma shows acceptable outcomes although more data are needed</p></li>
<li><p>Recent data on combined locoregional and immunotherapies demonstrate improvements in progression free survival, however further data in the setting of liver transplantation are needed</p></li>
</ul></section><section id="S0001"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Hepatocellular carcinoma (HCC) is the 4<sup>th</sup> leading cause of cancer death worldwide and a major cause of mortality in patients with compensated cirrhosis [<a href="#CIT0001" class="usa-link" aria-describedby="CIT0001">1</a>]. Approximately 80–90% of patients with HCC have underlying cirrhosis or chronic liver disease from hepatitis B, which are the main risk factors for HCC development and can serve as a competing risk of mortality in these patients [<a href="#CIT0002" class="usa-link" aria-describedby="CIT0002">2</a>,<a href="#CIT0003" class="usa-link" aria-describedby="CIT0003">3</a>]. The prognosis for HCC patients is closely linked to the stage at diagnosis, which incorporates tumor burden, functional status, and liver function, as outlined in the Barcelona Clinic Liver Cancer (BCLC) staging system [<a href="#CIT0004" class="usa-link" aria-describedby="CIT0004">4</a>]. Five-year survival in patients with early-stage disease can be as high as 70%, whereas it is less than 20% in patients with late-stage disease [<a href="#CIT0004" class="usa-link" aria-describedby="CIT0004">4</a>]. The high survival in early-stage HCC is largely due to eligibility for potentially curative therapies, including surgical resection, thermal ablation, and liver transplantation (LT). While surgical and ablative therapies can be effective in local tumor control, LT offers the added benefit of removal of the diseased liver, decreasing the risk of HCC recurrence and morbidity and mortality from underlying chronic liver disease [<a href="#CIT0005" class="usa-link" aria-describedby="CIT0005">5</a>]. LT has been traditionally offered for early-stage HCC; however, recent advances in locoregional (LRT) and systemic therapies have allowed patients with more advanced HCC to undergo LT [<a href="#CIT0006" class="usa-link" aria-describedby="CIT0006">6–8</a>]. Current rules for LT in patients with HCC in the United States require a 6 month waiting period on the waiting list prior to patients being granted a model of end-stage liver disease (MELD) exception score, therefore, waitlist management of HCC to maintain patients within transplant criteria, is also essential and has become increasingly complex [<a href="#CIT0009" class="usa-link" aria-describedby="CIT0009">9</a>].</p>
<p>This review aims to summarize current principles in patient selection for LT in HCC, focusing on the latest developments for downstaging, bridging therapies, and waitlist management.</p></section><section id="S0002"><h2 class="pmc_sec_title">2. Patient selection for liver transplant</h2>
<p>Determination of LT candidacy for patients with HCC is largely designed to minimize the risk of post-LT HCC recurrence while also maintaining access to transplantation. Multiple selection criteria based on tumor burden have been proposed for LT eligibility (<a href="#t0001" class="usa-link">Table 1</a>).</p>
<section class="tw xbox font-sm" id="t0001"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Examples of hepatocellular carcinoma transplant criteria. UCSF: University of California san francisco; AFP: alpha fetoprotein; UNOS-DS: United network of organ Sharing-Down staging.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col width="80pt" span="1">
<col width="80pt" span="1">
<col width="80pt" span="1">
<col width="80pt" span="1">
</colgroup>
<thead><tr>
<th align="left" colspan="1" rowspan="1">Criteria</th>
<th align="center" colspan="1" rowspan="1">Description</th>
<th align="center" colspan="1" rowspan="1">Post transplant survival</th>
<th align="center" colspan="1" rowspan="1">Post transplant recurrence free survival</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1">Milan criteria<sup>6</sup>
</td>
<td align="left" colspan="1" rowspan="1">1 lesion ≤ 5 cm or 3 distinct lesions ≤3 cm each</td>
<td align="left" colspan="1" rowspan="1">89% at 1 year<br>75% at 4 years<br>74% at 5 years</td>
<td align="left" colspan="1" rowspan="1">83% at 4 years</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">USCF criteria<sup>6</sup>
</td>
<td align="left" colspan="1" rowspan="1">1 lesion ≤6.5 cm or ≤ 3 tumors with the largest tumor diameter ≤ 4.5 cm and total tumor diameter ≤8 cm<br>No vascular invasion, no lymph node or distant metastasis</td>
<td align="left" colspan="1" rowspan="1">75% at 5 years<sup>11</sup>
</td>
<td align="left" colspan="1" rowspan="1">92.1% at 1 year<sup>6</sup><br>80.7% at 5 years<sup>6</sup>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Total Tumor Volume<br>+ AFP criteria<sup>12</sup>
</td>
<td align="left" colspan="1" rowspan="1">Total tumor volume ≤115cm<sup>3</sup><br>and AFP serum &lt; 400 ng/ml</td>
<td align="left" colspan="1" rowspan="1">74.6% at 4 years</td>
<td align="left" colspan="1" rowspan="1">68% at 4 years</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">UNOS-DS<sup>10</sup>
</td>
<td align="left" colspan="1" rowspan="1">1 lesion &gt; 5 cm but ≤ 8 cm<br>2-3 lesions with at least 1 lesion &gt; 3 cm, each lesion ≤ 5 cm and the total size ≤ to 8 cm.<br>4-5 lesions &lt; 3 cm and with the total diameter of all lesions &lt; 8 cm</td>
<td align="left" colspan="1" rowspan="1">94% at 1 year<sup>13</sup><br>74% at 5 years<sup>13</sup>
</td>
<td align="left" colspan="1" rowspan="1"> </td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>The Milan Criteria (MC) have been the most widely used and validated criteria for selecting patients for LT. MC criteria include a patient with one tumor ≥2 cm or ≤5 cm in diameter, or up to 3 tumors ≥1 or <span xmlns:mml="http://www.w3.org/1998/Math/MathML" id="ilm0001"><math id="MATH0001" display="inline"><mrow><mo>≤</mo></mrow></math></span>3 cm in diameter, without evidence of vascular invasion or extrahepatic disease [<a href="#CIT0010" class="usa-link" aria-describedby="CIT0010">10</a>]. In the original study defining the MC, 4-year post-transplant survival and recurrence-free survival was 75% and 83% respectively, with these outcomes subsequently validated in thousands of patients undergoing LT [<a href="#CIT0006" class="usa-link" aria-describedby="CIT0006">6</a>].</p>
<p>However, due to the restrictive nature of MC, numerous alternative criteria have been proposed to expand the number of patients that would be eligible for LT. Alternative criteria generally expand the tumor burden for LT or incorporate markers of tumor biology, such as serum alpha-fetoprotein (AFP) or tumor biopsy findings. One such set of criteria, the University of California San Francisco (UCSF) criteria expands tumor burden limits for LT, and includes patients that have 1 tumor less than 6.5 cm or up to three tumors less than 4.5 cm in size, a total tumor diameter of &lt; = 8 cm, no vascular invasion, and no extrahepatic metastasis [<a href="#CIT0011" class="usa-link" aria-describedby="CIT0011">11</a>]. An example of the integration of tumor biology into selection is the extended Toronto criteria [<a href="#CIT0012" class="usa-link" aria-describedby="CIT0012">12</a>]. Patients are considered for LT regardless of tumor size or number, provided they do not have any extrahepatic disease or macrovascular invasion, and a biopsy of the dominant lesion shows no evidence of poordifferentiation. Patients transplanted under these criteria had a 5-year survival rate of 68%, which, although acceptable, was lower than seen in patients within MC (76%). AFP levels also play a role in patient selection, as AFP values correlate with risk of microvascular invasion and post-LT recurrence [<a href="#CIT0013" class="usa-link" aria-describedby="CIT0013">13</a>,<a href="#CIT0014" class="usa-link" aria-describedby="CIT0014">14</a>]. Current Organ Procurement and Transplantation Network (OPTN) guidelines exclude patients with AFP levels &gt; 1000 ng/mL or &gt;500 ng/mL if the value was previously &gt;1000 ng/mL [<a href="#CIT0015" class="usa-link" aria-describedby="CIT0015">15</a>]. Novel biomarkers have been tested in HCC, with a single center study showing the AFP-L3 and des-gamma-carboxy prothrombin (DCP) can provide additional benefit over AFP alone in prognosticating waitlist dropout due to HCC progression and post-LT HCC recurrence. These data are promising, but require larger scale validation prior to being integrated into transplant selection criteria [<a href="#CIT0016" class="usa-link" aria-describedby="CIT0016">16</a>,<a href="#CIT0017" class="usa-link" aria-describedby="CIT0017">17</a>].</p>
<p>Given the current waitlist dynamics in many centers worldwide and the widespread availability of locoregional therapies for HCC treatment, there remains a question of whether patients with extended criteria should be routinely downstaged to within MC while on the waiting list, as tumor response to LRT is a strong predictor of recurrence-free survival after LT [<a href="#CIT0018" class="usa-link" aria-describedby="CIT0018">18</a>]. However, locoregional therapies may compromise liver function and potentially increase the risk of waitlist dropout [<a href="#CIT0019" class="usa-link" aria-describedby="CIT0019">19</a>]. Consideration of LT in patients with extended criteria HCC should likely be limited to situations where safe downstaging with locoregional therapy is not feasible due to compromised liver function.</p>
<p>Therefore, despite the evidence suggesting acceptable outcomes with expanded criteria, patients with HCC in the US are only eligible for a MELD exception for LT if they are within MC. When patients present beyond MC, they can be downstaged to within MC using locoregional or systemic therapy. Standardized downstaging criteria, called the UNOS-DS criteria, mirror the UCSF criteria. Patient meeting these criteria can receive a standard MELD exception once they are downstaged to MC, whereas downstaged patients who initially present beyond UNOS-DS criteria can be granted exceptions on a case-by-case basis after review by the UNOS National Review Board [<a href="#CIT0008" class="usa-link" aria-describedby="CIT0008">8</a>,<a href="#CIT0020" class="usa-link" aria-describedby="CIT0020">20</a>]. Downstaging patients to within MC using locoregional therapies is successful in over 80% of patients [<a href="#CIT0008" class="usa-link" aria-describedby="CIT0008">8</a>]. Rates of post-LT HCC recurrence and graft survival have been shown to be equivalent between patients transplanted within MC and UNOS-DS criteria [<a href="#CIT0007" class="usa-link" aria-describedby="CIT0007">7</a>]. Patients meeting these criteria have a 3-year survival and recurrence rates of 83.1% and 7.9%, respectively [<a href="#CIT0007" class="usa-link" aria-describedby="CIT0007">7</a>]. Patients with more advanced tumor burden but without extrahepatic disease can also be downstaged; however, this is often less successful with downstaging rates of 69%. Notably these patients had similar post-LT outcomes to those who met UNOS-DS criteria [<a href="#CIT0007" class="usa-link" aria-describedby="CIT0007">7</a>,<a href="#CIT0021" class="usa-link" aria-describedby="CIT0021">21</a>]. The XXL trial randomized 45 patients beyond MC to LT vs usual care. Patients who underwent LT after downstaging had significantly improved 5-year overall survival compared to those who did not undergo LT (77.5% vs 31.2%; <em>p</em> = 0.035) [<a href="#CIT0022" class="usa-link" aria-describedby="CIT0022">22</a>]. Algorithms for waitlist management based on initial tumor burden are outlined in <a href="#F0001" class="usa-link">Figure 1a–c</a>.</p>
<figure class="fig xbox font-sm" id="F0001"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377145_IHEP_A_2549676_F0001_C.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87a6/12377145/cc3cab64b816/IHEP_A_2549676_F0001_C.jpg" loading="lazy" height="235" width="750" alt="Figure 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/F0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flow chart for management of patients with hepatocellular carcinoma prior to liver transplantation, a) within Milan criteria; b) beyond Milan criteria but beyond UNOS-DS criteria; c) beyond UNOS-DS criteria without extrahepatic disease. HCC – hepatocellular carcinoma; UNOS- United Network of Organ Sharing; DS: Downstaging; LRT: locoregional therapy; MELD: Model of end stage liver disease.</p></figcaption></figure><p>In addition to oncologic management, patients with HCC typically have underlying chronic liver disease or cirrhosis, and effective management of cirrhosis and its complications is essential to maintaining waitlist eligibility. This includes providing adequate nutritional counseling and physical therapy to prevent frailty and sarcopenia, which can lead to waitlist dropout [<a href="#CIT0003" class="usa-link" aria-describedby="CIT0003">3</a>,<a href="#CIT0023" class="usa-link" aria-describedby="CIT0023">23</a>,<a href="#CIT0024" class="usa-link" aria-describedby="CIT0024">24</a>].</p></section><section id="S0003"><h2 class="pmc_sec_title">3. Locoregional therapy for bridging and downstaging</h2>
<p>Bridging or downstaging patients with HCC for LT can be achieved through a variety of modalities, including locoregional therapies (thermal ablation, transarterial therapies, and external radiation) and systemic therapies, or a multimodal approach [<a href="#CIT0025" class="usa-link" aria-describedby="CIT0025">25</a>]. All decisions regarding bridging and downstaging should be made in the setting of a multidisciplinary liver tumor board, which has been shown to improve patient outcomes [<a href="#CIT0026" class="usa-link" aria-describedby="CIT0026">26</a>]. The goals of bridging are to prevent disease progression while awaiting LT and to serve as a test of tumor biology. Response to therapy is a proxy for reduced risk of waitlist dropout, improved pathological response on explant, and decreased risk of recurrence after LT [<a href="#CIT0027" class="usa-link" aria-describedby="CIT0027">27</a>,<a href="#CIT0028" class="usa-link" aria-describedby="CIT0028">28</a>]. Factors associated with the risk of transplant waitlist dropout include: larger tumor size, number of tumors, lack of complete response after locoregional therapy, and AFP &gt; 20 ng/ml post-treatment [<a href="#CIT0029" class="usa-link" aria-describedby="CIT0029">29</a>]. Notably, the benefits of bridging therapies for patients listed within MC have not been evaluated prospectively. The Recent data suggest that bridging therapies may not provide a survival benefit or result in a reduction in post-LT recurrence for patients listed for LT with HCC [<a href="#CIT0030" class="usa-link" aria-describedby="CIT0030">30</a>]. On the other hand, several studies have shown that complete pathological necrosis prior to LT with LRTs can lead to improvements in post-LT outcomes [<a href="#CIT0031" class="usa-link" aria-describedby="CIT0031">31</a>]. Biases in the existing literature limit any conclusions as to the benefits of bridging therapy prior to LT.</p>
<section id="S0003-S2001"><h3 class="pmc_sec_title">3.1. Transarterial chemoembolization (TACE)</h3>
<p>TACE involves embolizing the hepatic artery branch supplying the tumor(s) while delivering local chemotherapy, typically doxorubicin or irinotecan, into the tumor vasculature. TACE can be performed with lipiodol (conventional TACE) or with drug eluting beads (DEB-TACE) and can be administered in a lobar or super-selective manner. Data suggest a selective approach yields the highest rates of tumor control [<a href="#CIT0033" class="usa-link" aria-describedby="CIT0033">33</a>,<a href="#CIT0034" class="usa-link" aria-describedby="CIT0034">34</a>]. The most common complication of TACE is post-embolization syndrome - a constellation of symptoms including: fever, fatigue, abdominal pain, and leukocytosis, largely resulting from tumor necrosis. Less common complications include: liver infarcts, ischemic biliopathy, cholecystitis, systemic embolism, and liver failure [<a href="#CIT0034" class="usa-link" aria-describedby="CIT0034">34</a>].</p>
<p>TACE may not benefit patients with bilobar multifocal disease, macrovascular invasion, tumors involving &gt;50% of the liver parenchyma, AFP levels &gt;400 ng/mL, or decompensated cirrhosis [<a href="#CIT0035" class="usa-link" aria-describedby="CIT0035">35</a>]. While TACE can be administered repeatedly, the need for more than three treatments is considered TACE-refractoriness, typically reflecting poor tumor biology. Repeated TACE increases the risk of hepatic decompensation and liver-related mortality [<a href="#CIT0036" class="usa-link" aria-describedby="CIT0036">36</a>,<a href="#CIT0037" class="usa-link" aria-describedby="CIT0037">37</a>].</p>
<p>Several studies have shown that TACE is an effective means of keeping patients within Milan criteria while awaiting LT, with the caveat that TACE can lead to worsening hepatic decompensation and dropout in a small percentage of patients [<a href="#CIT0038" class="usa-link" aria-describedby="CIT0038">38</a>,<a href="#CIT0039" class="usa-link" aria-describedby="CIT0039">39</a>]. Pre-LT TACE has not been associated with increased risk of artierial complication in the post-LT setting, despite its embolic nature [<a href="#CIT0040" class="usa-link" aria-describedby="CIT0040">40</a>]. TACE has also been shown to be effective in downstaging patients who are outside of MC, with equivalent results to transarterial radioembolization in achieving downstaging [<a href="#CIT0007" class="usa-link" aria-describedby="CIT0007">7</a>].</p>
<p>From 2003 to 2018 in the United States (US), transarterial chemoembolization (TACE) was the most frequently applied therapy, however, recent trends have shown that transarterial radioembolization (TARE) has become the most common means of bridging or downstaging patients [<a href="#CIT0032" class="usa-link" aria-describedby="CIT0032">32</a>].</p></section><section id="S0003-S2002"><h3 class="pmc_sec_title">3.2. Transarterial radioembolization (TARE)</h3>
<p>TARE involves targeted delivery of microspheres loaded with a radioactive Yttrium-90 with the goal of delivering high dose radiation to the tumor bed. Depending on tumor burden, TARE is typically administered using a lobar approach with a conventional radiation dose, or a segmental/lobar approach with a high ablative dose. The latter has been associated with high rates of complete pathological necrosis [<a href="#CIT0041" class="usa-link" aria-describedby="CIT0041">41–43</a>]. Complications of TARE include: off-target radiation effects (e.g., radiation pneumonitis), and radiation-induced liver disease, which may lead to hepatic decompensation [<a href="#CIT0043" class="usa-link" aria-describedby="CIT0043">43</a>].</p>
<p>The TRACE trial reported longer time to progression (17.1 vs. 9.5 months) and overall survival (30.2 vs. 15.6 months) for Y90 TARE compared to DEB-TACE in patients with BCLC stage A or B HCC [<a href="#CIT0044" class="usa-link" aria-describedby="CIT0044">44</a>]. The LEGACY study demonstrated that high-dose personalized dosimetry results in high rates of complete response in patients with early-stage HCC[<a href="#CIT0041" class="usa-link" aria-describedby="CIT0041">41</a>]. The MERITS-LT consortium, a prospective multi-regional study from the US, analyzed the rates of successful downstaging to within MC with embolization treatments (TACE and TARE). No significant differences were found between TACE and TARE for successful downstaging (&gt;80%), with both achieving similar 2-year post transplant survival of 95% [<a href="#CIT0007" class="usa-link" aria-describedby="CIT0007">7</a>].</p></section><section id="S0003-S2003"><h3 class="pmc_sec_title">3.3. Stereotactic body radiotherapy (SBRT)</h3>
<p>SBRT delivers fractionated, focused external radiation to destroy target tissue minimizing damage to surrounding structures [<a href="#CIT0045" class="usa-link" aria-describedby="CIT0045">45</a>]. Because of less adjacent organ injury, SBRT can treat lesions in challenging locations (e.g., diaphram), and can be used in patients with borderline liver function [<a href="#CIT0046" class="usa-link" aria-describedby="CIT0046">46</a>,<a href="#CIT0047" class="usa-link" aria-describedby="CIT0047">47</a>]. Retrospective cohort studies have shown that SBRT has superior local tumor control than both thermal ablation and TACE in retrospective analyses [<a href="#CIT0048" class="usa-link" aria-describedby="CIT0048">48</a>,<a href="#CIT0049" class="usa-link" aria-describedby="CIT0049">49</a>]. A recent prospective randomized trial showed that SBRT achieved superior local progression free survival when compared to radiofrequency ablation (hazard ratio [HR], 0.45 [95% CI, 0.24 to 0.87]) [<a href="#CIT0050" class="usa-link" aria-describedby="CIT0050">50</a>], In the setting of LT, SBRT achieves comparable outcomes to other LRT modalities, with similar dropout rates and post-LT outcomes [<a href="#CIT0039" class="usa-link" aria-describedby="CIT0039">39</a>].</p>
<p>Common complications of SBRT include: fatigue, nausea, and radiotherapy-induced liver disease (particularly in patients with a Child-Pugh score ≥ 8); however, significant toxicities seem to be rare, especially with the adoption of adaptive radiation dosing protocols [<a href="#CIT0047" class="usa-link" aria-describedby="CIT0047">47</a>,<a href="#CIT0051" class="usa-link" aria-describedby="CIT0051">51</a>,<a href="#CIT0052" class="usa-link" aria-describedby="CIT0052">52</a>]. There are limited data to support the routine use of SBRT in downstaging. However, one small single-center study demonstrated that SBRT can effectively downstage patients prior to LT [<a href="#CIT0053" class="usa-link" aria-describedby="CIT0053">53</a>].</p></section><section id="S0003-S2004"><h3 class="pmc_sec_title">3.4. Ablation techniques</h3>
<p>Ablative therapies for HCC include microwave/radiofrequency ablation, cryoablation, and histotripsy. Thermal ablation is typically reserved for tumors less than 3–4 cm in size, isolated from critical structures such as the diaphragm, heart, or major vessels [<a href="#CIT0054" class="usa-link" aria-describedby="CIT0054">54</a>]. Histotripsy can treat tumors up to 5 cm in diameter; however long-term outcomes data are lacking and its role in the setting of LT remains unstudied [<a href="#CIT0055" class="usa-link" aria-describedby="CIT0055">55</a>]. Outcomes after thermal ablation of small HCCs (≤ 3 cm) is excellent, with 5-year survival rates in excess of 70%, which was comparable to surgical resection in a randomized control trial [<a href="#CIT0056" class="usa-link" aria-describedby="CIT0056">56</a>].</p>
<p>Adverse events associated with thermal ablation are rare, but include bleeding, vascular thrombosis, pseudoaneurysm formation, biliary stenosis, cholecystitis, abscess formation, and tumor seeding.</p>
<p>Thermal ablative techniques are widely accepted modalities to bridge patients to LT. A 10-year intention to treat analysis of 121 patients receiving radiofrequency ablation showed that waitlist dropout occurred in 7.4% of patients, recurrence after transplantation occurred in 5.6% of patients. The post-transplantation intention to treat overall survival and recurrence-free survival rates at 5 years were 63.5% and 41.2% and at 10 years of 37.7% and 89.5% [<a href="#CIT0057" class="usa-link" aria-describedby="CIT0057">57</a>]. In a comparative analysis of patients with HCC within MC who received radiofrequency ablation versus those patients that did not while on the waitlist, patients who received radiofrequency ablation had significantly lower rates of dropout from the waitlist while experiencing no documented adverse effects from treatment that impacted waitlist status [<a href="#CIT0058" class="usa-link" aria-describedby="CIT0058">58</a>].</p></section></section><section id="S0004"><h2 class="pmc_sec_title">4. Immunotherapy as a bridging strategy for transplant</h2>
<p>With numerous recent approvals and widespread use of checkpoint inhibitor-based regimens for treating unresectable HCC, there is growing acceptance of use of systemic therapies in the LT setting [<a href="#CIT0059" class="usa-link" aria-describedby="CIT0059">59</a>]. Recent OPTN guidance allows patients to receive systemic therapy prior to transplantation as an acceptable strategy of bridging or downstaging. Neoadjuvant immunotherapy in a surgical setting is associated with major pathological responses in one-third of patients while improving post-resection recurrence-free survival [<a href="#CIT0060" class="usa-link" aria-describedby="CIT0060">60</a>]. However, in LT setting, we lack consensus on the optimal timing of immunotherapy relative to transplant to avoid rejection and graft loss[<a href="#CIT0061" class="usa-link" aria-describedby="CIT0061">61</a>,<a href="#CIT0062" class="usa-link" aria-describedby="CIT0062">62</a>].</p>
<p>Although we currently lack controlled prospective trials in this setting, multiple case series and meta-analyses have examined post-LT outcomes in the setting of checkpoint inhibitor therapy. In a series of 9 patients with HCC treated with nivolumab prior to LT, 1 patient had an episode of rejection in the post-LT setting while the other 8 had no significant adverse events [<a href="#CIT0063" class="usa-link" aria-describedby="CIT0063">63</a>]. A patient-level meta-analysis of 91 patients with received LT after immunotherapy reported 24 (26.4%) patients experienced post-LT rejection, 9 (9.9%) patients had HCC recurrence, and 9 (9.9%) died in follow-up [<a href="#CIT0064" class="usa-link" aria-describedby="CIT0064">64</a>]. Overall survival was not associated with allograft rejection, and the median immune checkpoint inhibitor washout period prior to transplant for patients with low rejection risk was 94 days. While these data support the safety of immune checkpoint inhibitors in the pre-LT setting with an appropriate washout period, the intention of ICI therapy was unclear in these patients (systemic treatment for advanced HCC vs intentional bridging/downstaging).</p>
<p>To address this gap, several prospective studies on the efficacy of immunotherapy in bridging to LT are underway (<a href="#t0002" class="usa-link">Table 2</a>). ImmunoXXL (NCT: <a href="https://clinicaltrials.gov/ct2/show/NCT05879328" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05879328</a>) is evaluating patients with HCC beyond AFP-adjusted up-to-seven criteria without extrahepatic disease or portal vein tumor thrombus. Enrolled patients will receive 3 or more cycles of atezolizumab and bevacizumab and must have a sustained downstaging of more than three months before being considered for transplant, with assessment of several post-LT outcomes, including rejection and recurrence [<a href="#CIT0059" class="usa-link" aria-describedby="CIT0059">59</a>]. The MERITS-LT prospective protocol is also evaluating the use of immunotherapy to bridge patients after successful downstaging by LRT if residual or recurrent disease is present while listed [<a href="#CIT0059" class="usa-link" aria-describedby="CIT0059">59</a>]. One of the main challenges of routine use of immunotherapy prior to LT is the unpredictability of organ availability end ensuring a sufficient checkpoint inhibitor washout period. Timed living donation may be ideal for these patients, otherwise, centers must balance the risk of post-LT rejection versus tumor progression while awaiting LT in patients receiving immunotherapy.</p>
<section class="tw xbox font-sm" id="t0002"><h3 class="obj_head">Table 2.</h3>
<div class="caption p"><p>Ongoing studies on HCC and transplantation; SBRT: stereotactic body radiation therapy; TACE: transarterial chemoembolization; UCSF: University of California san francisco.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col width="80pt" span="1">
<col width="80pt" span="1">
<col width="80pt" span="1">
<col width="80pt" span="1">
<col width="80pt" span="1">
</colgroup>
<thead><tr>
<th align="left" colspan="1" rowspan="1">Study name/identifier</th>
<th align="center" colspan="1" rowspan="1">Study phase</th>
<th align="center" colspan="1" rowspan="1">Treatments studied</th>
<th align="center" colspan="1" rowspan="1">Primary outcome</th>
<th align="center" colspan="1" rowspan="1">Study status</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1">ImmunoXXL (<a href="https://clinicaltrials.gov/ct2/show/NCT05879328" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05879328</a>)</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">Atezolizumab and Bevacizumab for downstaging</td>
<td align="left" colspan="1" rowspan="1">Recurrence-free survival up to 2-year post transplant</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05185505" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05185505</a></td>
<td align="left" colspan="1" rowspan="1">Phase 4</td>
<td align="left" colspan="1" rowspan="1">Atezolizumab and Bevacizumab<br>vs<br>TACE + Atezolizumab and Bevacizumab</td>
<td align="left" colspan="1" rowspan="1">Proportion of Patients Receiving Liver Transplant Experiencing Acute Rejection within 1 year</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT02081755" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02081755</a></td>
<td align="left" colspan="1" rowspan="1">Phase 4</td>
<td align="left" colspan="1" rowspan="1">Everolimus and tacrolimus<br>Vs<br>Tacrolimus and Myfortic or Cellcept or Imuran</td>
<td align="left" colspan="1" rowspan="1">Disease free survival defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first.</td>
<td align="left" colspan="1" rowspan="1">Active not recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TRANSRAD-01 (<a href="https://clinicaltrials.gov/ct2/show/NCT06218420" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06218420</a>)</td>
<td align="left" colspan="1" rowspan="1">Phase 2</td>
<td align="left" colspan="1" rowspan="1">SBRT to bridge for transplant</td>
<td align="left" colspan="1" rowspan="1">Efficacy of SBRT as bridging therapy</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01918683" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01918683</a></td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">TACE + SBRT vs TACE for bridging</td>
<td align="left" colspan="1" rowspan="1">Progression Free Survival</td>
<td align="left" colspan="1" rowspan="1">Active, not recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05576909" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05576909</a></td>
<td align="left" colspan="1" rowspan="1">Phase 2</td>
<td align="left" colspan="1" rowspan="1">Donefenib + TACE for downstaging</td>
<td align="left" colspan="1" rowspan="1">Downstaging success rate</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05475613" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05475613</a></td>
<td align="left" colspan="1" rowspan="1">Phase 2</td>
<td align="left" colspan="1" rowspan="1">Anti-PD-1 for downstaging</td>
<td align="left" colspan="1" rowspan="1">The 2-year event-free survival rate</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05913583" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05913583</a></td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">ICI exposure prior to liver transplantation vs non-ICI exposure</td>
<td align="left" colspan="1" rowspan="1">Graft rejection at one year</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04595864" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04595864</a></td>
<td align="left" colspan="1" rowspan="1">Phase 3</td>
<td align="left" colspan="1" rowspan="1">Transarterial chemoinfusion with mFOLFOX6<br>As neo-adjuvant for beyond Milan/UCSF HCC<br>Vs<br>No treatment</td>
<td align="left" colspan="1" rowspan="1">Overall survival up to 60 months</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PLENTY202001<br>(<a href="https://clinicaltrials.gov/ct2/show/NCT04425226" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04425226</a>)</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
<td align="left" colspan="1" rowspan="1">Pembrolizumab + lenvatinib<br>Vs no treatment</td>
<td align="left" colspan="1" rowspan="1">Recurrence-Free Survival up to 4 years</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05027425" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05027425</a></td>
<td align="left" colspan="1" rowspan="1">Phase 2</td>
<td align="left" colspan="1" rowspan="1">Durvalumab + Tremelimumab + Liver Transplant</td>
<td align="left" colspan="1" rowspan="1">Cellular rejection rates up to 30 days post transplant</td>
<td align="left" colspan="1" rowspan="1">Recruiting</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="S0005"><h2 class="pmc_sec_title">5. Locoregional therapy and immunotherapy combination strategies</h2>
<p>Two of the primary metrics for patients with HCC being considered for LT includes minimizing risk of waitlist dropout and risk of HCC recurrence post-LT. Given the suboptimal response rates in some patients receiving both LRT and systemic therapy alone, the combination of locoregional therapy and immune checkpoint inhibitor-based immunotherapies are being evaluated in patients with intermediate-stage HCC. The promise of longer progression free survival and higher rates of major pathological response through the administration of immunotherapy with locoregional therapy has made this approach an active area of investigation.</p>
<p>The largest phase 3 studies combining TACE plus immunotherapy include the EMERALD-1 and the LEAP-012. EMERALD-1 studied the combination of TACE plus durvalumab and bevacizumab in patients with intermediate stage HCC, with results meeting the primary endpoint of progression-free survival benefit (15 months vs 8.2 months in placebo plus TACE arm; HR 0.77 [95% CI 0.61–0.98]) [<a href="#CIT0065" class="usa-link" aria-describedby="CIT0065">65</a>]. LEAP-012 studied the combination of pembrolizumab and lenvatinib combined with TACE and the combination had a significantly longer median progression-free survival compared to TACE plus placebo (14.6 months vs 10.0 months; HR: 0.66 [95% CI 0·51–0·84]) compared with TACE alone [<a href="#CIT0066" class="usa-link" aria-describedby="CIT0066">66</a>]. Adverse events were manageable in both trials, but there were several patients with grade 5 toxicities in the study drug arms of both trials. Furthermore, the data are not yet mature for overall survival outcomes. The utility of these combined modalities remains unclear in the context of LT and more data is necessary.</p>
<p>The combination of hepatic arterial infusion therapy plus systemic therapy has been shown to improve outcomes in patients with advanced HCC, however, we lack data role of this approach in patients awaiting LT[<a href="#CIT0067" class="usa-link" aria-describedby="CIT0067">67</a>]. Furthermore, hepatic arterial pumps may increase the perioperative LT risk due to hepatic arterial injury [<a href="#CIT0068" class="usa-link" aria-describedby="CIT0068">68</a>]. There are several ongoing phase 3 and earlier phase studies combining other locoregional therapies with immunotherapy combinations [<a href="#CIT0069" class="usa-link" aria-describedby="CIT0069">69</a>].</p></section><section id="S0006"><h2 class="pmc_sec_title">6. Conclusion</h2>
<p>HCC is a major cause of morbidity and mortality worldwide, and while a small minority of patients ultimately receive an LT, LT provides superior long-term outcomes compared to other available therapies. To optimize patient outcomes, patient selection and stewardship while awaiting LT is essential. Locoregional therapies are currently the most commonly used treatments to bridge or downstage patients to LT and have shown excellent success in eligible patients. Recent data on immunotherapy prior to LT is a promising strategy to complement current strategies and may allow the expansion of eligibility for LT.</p></section><section id="S0007"><h2 class="pmc_sec_title">7. Future perspectives</h2>
<p>There have been several developments in the treatment of HCC, including novel applications of current systemic therapies in combination with locoregional therapies, novel combinations of systemic therapies, and systemic therapies targeting alternate anti-tumor pathways. As data for systemic therapies for HCC mature, integration of these treatments into bridging or downstaging protocols prior to LT will be necessary. Specifically, the regimen type, timing/duration, and patient selection will require further data to be routinely integrated into current algorithms prior to LT. Ongoing prospective trials, such as ImmunoXXL, will help better define these parameters for the use of immunotherapy prior to LT. The current data on post-LT outcomes in the setting of immunotherapy appears promising, however, we require further evidence on the benefits and potential risks of immunotherapy regimens, particularly as alternate immune pathways are targeted.</p></section><section id="S0008"><h2 class="pmc_sec_title">Authors’ contributions</h2>
<p>Antoine Robert: Writing original draft; Thomas Hunold: Writing review and editing; Neehar Parikh: Conceptualization, Writing review and editing.</p></section><section id="S0009"><h2 class="pmc_sec_title">Disclosure statement</h2>
<p>Neehar Parikh serves as a consultant for Exact Sciences, AstraZeneca, and Sirtex, and has served on advisory boards of Genentech, Eisai, Bayer, Exelixis, Wako/Fujifilm and has received research funding from Bayer, Exact Sciences, Genentech, and Glycotest.</p>
<p>The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p>
<p>No writing assistance was utilized in the production of this manuscript.</p></section><section id="S0010"><h2 class="pmc_sec_title">Reviewer disclosures</h2>
<p>Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<p>Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.</p>
<section id="ref-list1_sec1"><section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CIT0001">
<span class="label">1.</span><cite>Bray F, Laversanne M, Sung H, et al. 
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834
</cite> [<a href="https://doi.org/10.3322/caac.21834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38572751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=Global%20cancer%20statistics%202022:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;volume=74&amp;issue=3&amp;publication_year=2024&amp;pages=229-263&amp;pmid=38572751&amp;doi=10.3322/caac.21834&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0002">
<span class="label">2.</span><cite>Reddy KR, McLerran D, Marsh T, et al. 
Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the multicenter hepatocellular carcinoma early detection strategy (HEDS) study. Gastroenterology. 2023;165(4):1053–1063. e6. doi: 10.1053/j.gastro.2023.06.027
</cite> [<a href="https://doi.org/10.1053/j.gastro.2023.06.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10529044/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37429366/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Incidence%20and%20risk%20factors%20for%20hepatocellular%20carcinoma%20in%20cirrhosis:%20the%20multicenter%20hepatocellular%20carcinoma%20early%20detection%20strategy%20(HEDS)%20study&amp;volume=165&amp;issue=4&amp;publication_year=2023&amp;pages=1053-1063.%20e6&amp;pmid=37429366&amp;doi=10.1053/j.gastro.2023.06.027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0003">
<span class="label">3.</span><cite>Tapper EB, Parikh ND.. 
Diagnosis and management of cirrhosis and its complications: A review. Jama. 2023;329(18):1589–1602. doi: 10.1001/jama.2023.5997
</cite> [<a href="https://doi.org/10.1001/jama.2023.5997" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10843851/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37159031/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Jama&amp;title=Diagnosis%20and%20management%20of%20cirrhosis%20and%20its%20complications:%20A%20review&amp;volume=329&amp;issue=18&amp;publication_year=2023&amp;pages=1589-1602&amp;pmid=37159031&amp;doi=10.1001/jama.2023.5997&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0004">
<span class="label">4.</span><cite>Reig M, Forner A, Rimola J, et al. 
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–693. doi: 10.1016/j.jhep.2021.11.018
</cite> [<a href="https://doi.org/10.1016/j.jhep.2021.11.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8866082/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34801630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=BCLC%20strategy%20for%20prognosis%20prediction%20and%20treatment%20recommendation:%20The%202022%20update&amp;volume=76&amp;issue=3&amp;publication_year=2022&amp;pages=681-693&amp;pmid=34801630&amp;doi=10.1016/j.jhep.2021.11.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0005">
<span class="label">5.</span><cite>Kanneganti M, Mahmud N, Kaplan DE, et al. 
Survival benefit of liver transplantation for hepatocellular carcinoma. Transplantation. 2020;104(1):104–112. doi: 10.1097/TP.0000000000002816
</cite> [<a href="https://doi.org/10.1097/TP.0000000000002816" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6928443/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31283688/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplantation&amp;title=Survival%20benefit%20of%20liver%20transplantation%20for%20hepatocellular%20carcinoma&amp;volume=104&amp;issue=1&amp;publication_year=2020&amp;pages=104-112&amp;pmid=31283688&amp;doi=10.1097/TP.0000000000002816&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0006">
<span class="label">6.</span><cite>Mazzaferro V, Bhoori S, Sposito C, et al. 
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence‐based analysis of 15 years of experience. Liver Transpl. 2011;17 (Supplement 2):S44–S57. doi: 10.1002/lt.22365
</cite> [<a href="https://doi.org/10.1002/lt.22365" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21695773/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&amp;title=Milan%20criteria%20in%20liver%20transplantation%20for%20hepatocellular%20carcinoma:%20an%20evidence%E2%80%90based%20analysis%20of%2015%20years%20of%20experience&amp;volume=17&amp;issue=Supplement%202&amp;publication_year=2011&amp;pages=S44-S57&amp;pmid=21695773&amp;doi=10.1002/lt.22365&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0007">
<span class="label">7.</span><cite>Mehta N, Frenette C, Tabrizian P, et al. 
Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium. Gastroenterology. 2021;161(5):1502–1512. doi: 10.1053/j.gastro.2021.07.033
</cite> [<a href="https://doi.org/10.1053/j.gastro.2021.07.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8545832/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34331914/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Downstaging%20outcomes%20for%20hepatocellular%20carcinoma:%20results%20from%20the%20multicenter%20evaluation%20of%20reduction%20in%20tumor%20size%20before%20liver%20transplantation%20(MERITS-LT)%20consortium&amp;volume=161&amp;issue=5&amp;publication_year=2021&amp;pages=1502-1512&amp;pmid=34331914&amp;doi=10.1053/j.gastro.2021.07.033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0008">
<span class="label">8.</span><cite>Parikh ND, Waljee AK, Singal AG.. 
Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21(9):1142–1152. doi: 10.1002/lt.24169
</cite> [<a href="https://doi.org/10.1002/lt.24169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25981135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&amp;title=Downstaging%20hepatocellular%20carcinoma:%20a%20systematic%20review%20and%20pooled%20analysis&amp;volume=21&amp;issue=9&amp;publication_year=2015&amp;pages=1142-1152&amp;pmid=25981135&amp;doi=10.1002/lt.24169&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0009">
<span class="label">9.</span><cite>Lopez PM, Villanueva A, Roayaie S, et al. 
Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl. 2006;12(12):1747–1754. doi: 10.1002/lt.21018
</cite> [<a href="https://doi.org/10.1002/lt.21018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17133591/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&amp;title=Neoadjuvant%20therapies%20for%20hepatocellular%20carcinoma%20before%20liver%20transplantation:%20a%20critical%20appraisal&amp;volume=12&amp;issue=12&amp;publication_year=2006&amp;pages=1747-1754&amp;pmid=17133591&amp;doi=10.1002/lt.21018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0010">
<span class="label">10.</span><cite>Mazzaferro V, Regalia E, Doci R, et al. 
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. doi: 10.1056/NEJM199603143341104
</cite> [<a href="https://doi.org/10.1056/NEJM199603143341104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8594428/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Liver%20transplantation%20for%20the%20treatment%20of%20small%20hepatocellular%20carcinomas%20in%20patients%20with%20cirrhosis&amp;volume=334&amp;issue=11&amp;publication_year=1996&amp;pages=693-699&amp;pmid=8594428&amp;doi=10.1056/NEJM199603143341104&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0011">
<span class="label">11.</span><cite>Yao FY, Ferrell L, Bass NM, et al. 
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8(9):765–774. doi: 10.1053/jlts.2002.34892
</cite> [<a href="https://doi.org/10.1053/jlts.2002.34892" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12200775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&amp;title=Liver%20transplantation%20for%20hepatocellular%20carcinoma:%20comparison%20of%20the%20proposed%20UCSF%20criteria%20with%20the%20Milan%20criteria%20and%20the%20Pittsburgh%20modified%20TNM%20criteria&amp;volume=8&amp;issue=9&amp;publication_year=2002&amp;pages=765-774&amp;pmid=12200775&amp;doi=10.1053/jlts.2002.34892&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0012">
<span class="label">12.</span><cite>Sapisochin G, Goldaracena N, Laurence JM, et al. 
The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64(6):2077–2088. doi: 10.1002/hep.28643
</cite> [<a href="https://doi.org/10.1002/hep.28643" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27178646/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=The%20extended%20Toronto%20criteria%20for%20liver%20transplantation%20in%20patients%20with%20hepatocellular%20carcinoma:%20a%20prospective%20validation%20study&amp;volume=64&amp;issue=6&amp;publication_year=2016&amp;pages=2077-2088&amp;pmid=27178646&amp;doi=10.1002/hep.28643&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0013">
<span class="label">13.</span><cite>Yeo YH, Lee Y-T, Tseng H-R, et al. 
Alpha-fetoprotein: Past, present, and future. Hepatol Commun. 2024;8(5):e0422. doi: 10.1097/HC9.0000000000000422
</cite> [<a href="https://doi.org/10.1097/HC9.0000000000000422" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11019827/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38619448/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatol%20Commun&amp;title=Alpha-fetoprotein:%20Past,%20present,%20and%20future&amp;volume=8&amp;issue=5&amp;publication_year=2024&amp;pages=e0422&amp;pmid=38619448&amp;doi=10.1097/HC9.0000000000000422&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0014">
<span class="label">14.</span><cite>Hakeem A, Young R, Marangoni G, et al. 
Systematic review: the prognostic role of alpha‐fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35(9):987–999. doi: 10.1111/j.1365-2036.2012.05060.x
</cite> [<a href="https://doi.org/10.1111/j.1365-2036.2012.05060.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22429190/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Aliment%20Pharmacol%20Ther&amp;title=Systematic%20review:%20the%20prognostic%20role%20of%20alpha%E2%80%90fetoprotein%20following%20liver%20transplantation%20for%20hepatocellular%20carcinoma&amp;volume=35&amp;issue=9&amp;publication_year=2012&amp;pages=987-999&amp;pmid=22429190&amp;doi=10.1111/j.1365-2036.2012.05060.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0015">
<span class="label">15.</span><cite>Ruch B, Wagler J, Kumm K, et al. 
Hepatocellular carcinoma, alpha fetoprotein, and liver allocation for transplantation: past, present and future. Curr Oncol. 2022;29(10):7537–7551. doi: 10.3390/curroncol29100593
</cite> [<a href="https://doi.org/10.3390/curroncol29100593" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9600271/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36290870/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Oncol&amp;title=Hepatocellular%20carcinoma,%20alpha%20fetoprotein,%20and%20liver%20allocation%20for%20transplantation:%20past,%20present%20and%20future&amp;volume=29&amp;issue=10&amp;publication_year=2022&amp;pages=7537-7551&amp;pmid=36290870&amp;doi=10.3390/curroncol29100593&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0016">
<span class="label">16.</span><cite>*Norman JS, Li PJ, Kotwani P, et al. 
AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023;79(6):1469–1477. doi: 10.1016/j.jhep.2023.08.020
</cite> [<a href="https://doi.org/10.1016/j.jhep.2023.08.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10998694/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37683735/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=AFP-L3%20and%20DCP%20strongly%20predict%20early%20hepatocellular%20carcinoma%20recurrence%20after%20liver%20transplantation&amp;volume=79&amp;issue=6&amp;publication_year=2023&amp;pages=1469-1477&amp;pmid=37683735&amp;doi=10.1016/j.jhep.2023.08.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>This study details the utility of AFP-L3 and DCP in the setting of liver transplant selection criteria.</cite>
</li>
<li id="CIT0017">
<span class="label">17.</span><cite>Mehta N, Kotwani P, Norman J, et al. 
AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study. Liver Transpl. 2023;29(10):1041–1049. doi: 10.1097/LVT.0000000000000149
</cite> [<a href="https://doi.org/10.1097/LVT.0000000000000149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10523909/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37159217/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transpl&amp;title=AFP-L3%20and%20DCP%20are%20superior%20to%20AFP%20in%20predicting%20waitlist%20dropout%20in%20HCC%20patients:%20Results%20of%20a%20prospective%20study&amp;volume=29&amp;issue=10&amp;publication_year=2023&amp;pages=1041-1049&amp;pmid=37159217&amp;doi=10.1097/LVT.0000000000000149&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0018">
<span class="label">18.</span><cite>DiNorcia J, Florman SS, Haydel B, et al. 
Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US multicenter HCC transplant consortium. Ann Surg. 2020;271(4):616–624. doi: 10.1097/SLA.0000000000003253
</cite> [<a href="https://doi.org/10.1097/SLA.0000000000003253" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30870180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg&amp;title=Pathologic%20response%20to%20pretransplant%20locoregional%20therapy%20is%20predictive%20of%20patient%20outcome%20after%20liver%20transplantation%20for%20hepatocellular%20carcinoma:%20analysis%20from%20the%20US%20multicenter%20HCC%20transplant%20consortium&amp;volume=271&amp;issue=4&amp;publication_year=2020&amp;pages=616-624&amp;pmid=30870180&amp;doi=10.1097/SLA.0000000000003253&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0019">
<span class="label">19.</span><cite>Mehta N, Kelley RK, Yao FY.. 
Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies. Hepatology. 2024;80(1):238–253. doi: 10.1097/HEP.0000000000000452
</cite> [<a href="https://doi.org/10.1097/HEP.0000000000000452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37183865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Refining%20the%20approach%20to%20down-staging%20of%20HCC%20prior%20to%20liver%20transplantation:%20Patient%20selection,%20loco-regional%20treatments,%20and%20systemic%20therapies&amp;volume=80&amp;issue=1&amp;publication_year=2024&amp;pages=238-253&amp;pmid=37183865&amp;doi=10.1097/HEP.0000000000000452&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0020">
<span class="label">20.</span><cite>**Tabrizian P, Holzner ML, Mehta N, et al. 
Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022;157(9):779–788. doi: 10.1001/jamasurg.2022.2800
</cite> [<a href="https://doi.org/10.1001/jamasurg.2022.2800" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9301590/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35857294/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Surg&amp;title=Ten-year%20outcomes%20of%20liver%20transplant%20and%20downstaging%20for%20hepatocellular%20carcinoma&amp;volume=157&amp;issue=9&amp;publication_year=2022&amp;pages=779-788&amp;pmid=35857294&amp;doi=10.1001/jamasurg.2022.2800&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>There are acceptable long term outcomes for patients with hepatocellular carcinoma downstaged prior to liver transplantation.</cite>
</li>
<li id="CIT0021">
<span class="label">21.</span><cite>Huang AC, Dodge JL, Yao FY, et al. 
National experience on waitlist outcomes for down-staging of hepatocellular carcinoma: high dropout rate in all-comers. Clin Gastroenterol Hepatol. 2023;21(6):1581–1589. doi: 10.1016/j.cgh.2022.08.023
</cite> [<a href="https://doi.org/10.1016/j.cgh.2022.08.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36038129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&amp;title=National%20experience%20on%20waitlist%20outcomes%20for%20down-staging%20of%20hepatocellular%20carcinoma:%20high%20dropout%20rate%20in%20all-comers&amp;volume=21&amp;issue=6&amp;publication_year=2023&amp;pages=1581-1589&amp;pmid=36038129&amp;doi=10.1016/j.cgh.2022.08.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0022">
<span class="label">22.</span><cite>Mazzaferro V, Citterio D, Bhoori S, et al. 
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21(7):947–956. doi: 10.1016/S1470-2045(20)30224-2
</cite> [<a href="https://doi.org/10.1016/S1470-2045(20)30224-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32615109/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Liver%20transplantation%20in%20hepatocellular%20carcinoma%20after%20tumour%20downstaging%20(XXL):%20a%20randomised,%20controlled,%20phase%202b/3%20trial&amp;volume=21&amp;issue=7&amp;publication_year=2020&amp;pages=947-956&amp;pmid=32615109&amp;doi=10.1016/S1470-2045(20)30224-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0023">
<span class="label">23.</span><cite>Lai JC, Covinsky KE, McCulloch CE, et al. 
The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113(2):235–242. doi: 10.1038/ajg.2017.443
</cite> [<a href="https://doi.org/10.1038/ajg.2017.443" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5866923/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29231189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Gastroenterol&amp;title=The%20liver%20frailty%20index%20improves%20mortality%20prediction%20of%20the%20subjective%20clinician%20assessment%20in%20patients%20with%20cirrhosis&amp;volume=113&amp;issue=2&amp;publication_year=2018&amp;pages=235-242&amp;pmid=29231189&amp;doi=10.1038/ajg.2017.443&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0024">
<span class="label">24.</span><cite>Hammad A, Kaido T, Aliyev V, et al. 
Nutritional therapy in liver transplantation. Nutrients. 2017;9(10):1126. doi: 10.3390/nu9101126
</cite> [<a href="https://doi.org/10.3390/nu9101126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5691742/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29035319/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutrients&amp;title=Nutritional%20therapy%20in%20liver%20transplantation&amp;volume=9&amp;issue=10&amp;publication_year=2017&amp;pages=1126&amp;pmid=29035319&amp;doi=10.3390/nu9101126&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0025">
<span class="label">25.</span><cite>Yao FY, Mehta N, Flemming J, et al. 
Downstaging of hepatocellular cancer before liver transplant: long‐term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968–1977. doi: 10.1002/hep.27752
</cite> [<a href="https://doi.org/10.1002/hep.27752" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4809192/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25689978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Downstaging%20of%20hepatocellular%20cancer%20before%20liver%20transplant:%20long%E2%80%90term%20outcome%20compared%20to%20tumors%20within%20Milan%20criteria&amp;volume=61&amp;issue=6&amp;publication_year=2015&amp;pages=1968-1977&amp;pmid=25689978&amp;doi=10.1002/hep.27752&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0026">
<span class="label">26.</span><cite>El Dahan KS, Reczek A, Daher D, et al. 
Multidisciplinary care for patients with HCC: a systematic review and meta-analysis. Hepatol Commun. 2023;7(5):e0143. doi: 10.1097/HC9.0000000000000143
</cite> [<a href="https://doi.org/10.1097/HC9.0000000000000143" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10146543/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37102768/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatol%20Commun&amp;title=Multidisciplinary%20care%20for%20patients%20with%20HCC:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=7&amp;issue=5&amp;publication_year=2023&amp;pages=e0143&amp;pmid=37102768&amp;doi=10.1097/HC9.0000000000000143&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0027">
<span class="label">27.</span><cite>Sarwar A, Bonder A, Hassan L, et al. 
Factors associated with complete pathologic necrosis of hepatocellular carcinoma on explant evaluation after locoregional therapy: a national analysis using the UNOS database. AJR Am J Roentgenol. 2023;220(5):727–735. doi: 10.2214/AJR.22.28385
</cite> [<a href="https://doi.org/10.2214/AJR.22.28385" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36475810/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AJR%20Am%20J%20Roentgenol&amp;title=Factors%20associated%20with%20complete%20pathologic%20necrosis%20of%20hepatocellular%20carcinoma%20on%20explant%20evaluation%20after%20locoregional%20therapy:%20a%20national%20analysis%20using%20the%20UNOS%20database&amp;volume=220&amp;issue=5&amp;publication_year=2023&amp;pages=727-735&amp;pmid=36475810&amp;doi=10.2214/AJR.22.28385&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0028">
<span class="label">28.</span><cite>Xu M, Doyle MM, Banan B, et al. 
Neoadjuvant locoregional therapy and recurrent hepatocellular carcinoma after liver transplantation. J Am Coll Surg. 2017;225(1):28–40. doi: 10.1016/j.jamcollsurg.2017.03.015
</cite> [<a href="https://doi.org/10.1016/j.jamcollsurg.2017.03.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5777313/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28400300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Surg&amp;title=Neoadjuvant%20locoregional%20therapy%20and%20recurrent%20hepatocellular%20carcinoma%20after%20liver%20transplantation&amp;volume=225&amp;issue=1&amp;publication_year=2017&amp;pages=28-40&amp;pmid=28400300&amp;doi=10.1016/j.jamcollsurg.2017.03.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0029">
<span class="label">29.</span><cite>Mehta N, Dodge JL, Hirose R, et al. 
Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: implications for organ allocation. Am J Transplant. 2019;19(8):2210–2218. doi: 10.1111/ajt.15353
</cite> [<a href="https://doi.org/10.1111/ajt.15353" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7072024/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30861298/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=Predictors%20of%20low%20risk%20for%20dropout%20from%20the%20liver%20transplant%20waiting%20list%20for%20hepatocellular%20carcinoma%20in%20long%20wait%20time%20regions:%20implications%20for%20organ%20allocation&amp;volume=19&amp;issue=8&amp;publication_year=2019&amp;pages=2210-2218&amp;pmid=30861298&amp;doi=10.1111/ajt.15353&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0030">
<span class="label">30.</span><cite>Arvind A, El Dahan KS, Malhotra R, et al. 
Association between bridging therapy and post-transplant outcomes in patients with hepatocellular carcinoma within Milan criteria: A systematic review and meta-analysis. Liver Transplantation. 2024:30(6):595–606. doi: 10.1097/LVT.0000000000000357.</cite> [<a href="https://doi.org/10.1097/LVT.0000000000000357" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38466889/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Transplantation&amp;title=Association%20between%20bridging%20therapy%20and%20post-transplant%20outcomes%20in%20patients%20with%20hepatocellular%20carcinoma%20within%20Milan%20criteria:%20A%20systematic%20review%20and%20meta-analysis&amp;publication_year=2024&amp;pmid=38466889&amp;doi=10.1097/LVT.0000000000000357&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0031">
<span class="label">31.</span><cite>*Agopian VG, Morshedi MM, McWilliams J, et al. 
Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients. Ann Surg. 2015;262(3):536–545. doi: 10.1097/SLA.0000000000001384
</cite> [<a href="https://doi.org/10.1097/SLA.0000000000001384" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26258323/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg&amp;title=Complete%20pathologic%20response%20to%20pretransplant%20locoregional%20therapy%20for%20hepatocellular%20carcinoma%20defines%20cancer%20cure%20after%20liver%20transplantation:%20analysis%20of%20501%20consecutively%20treated%20patients&amp;volume=262&amp;issue=3&amp;publication_year=2015&amp;pages=536-545&amp;pmid=26258323&amp;doi=10.1097/SLA.0000000000001384&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>This paper demonstrates the benefits of complete pathological necrosis using locoregional therapies prior to liver transplant.</cite>
</li>
<li id="CIT0032">
<span class="label">32.</span><cite>Salem R, Kwong AJ, Kim N, et al. 
Yttrium-90 radioembolization has become the most utilized bridging treatment for liver transplant candidates in the United States. J Vasc Interv Radiol. 2025;36(2):362–363. doi: 10.1016/j.jvir.2024.10.034
</cite> [<a href="https://doi.org/10.1016/j.jvir.2024.10.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39522866/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Vasc%20Interv%20Radiol&amp;title=Yttrium-90%20radioembolization%20has%20become%20the%20most%20utilized%20bridging%20treatment%20for%20liver%20transplant%20candidates%20in%20the%20United%20States&amp;issue=2&amp;publication_year=2025&amp;pages=362-363&amp;pmid=39522866&amp;doi=10.1016/j.jvir.2024.10.034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0033">
<span class="label">33.</span><cite>Pleguezuelo M, Marelli L, Misseri M, et al. 
TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8(10):1623–1641. doi: 10.1586/14737140.8.10.1623
</cite> [<a href="https://doi.org/10.1586/14737140.8.10.1623" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18925854/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Anticancer%20Ther&amp;title=TACE%20versus%20TAE%20as%20therapy%20for%20hepatocellular%20carcinoma&amp;volume=8&amp;issue=10&amp;publication_year=2008&amp;pages=1623-1641&amp;pmid=18925854&amp;doi=10.1586/14737140.8.10.1623&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0034">
<span class="label">34.</span><cite>Lanza C, Ascenti V, Amato GV, et al. 
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement. J Clin Med. 2025;14(2):314. doi: 10.3390/jcm14020314
</cite> [<a href="https://doi.org/10.3390/jcm14020314" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11766109/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39860320/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&amp;title=All%20You%20Need%20to%20Know%20About%20TACE:%20A%20Comprehensive%20Review%20of%20Indications,%20Techniques,%20Efficacy,%20Limits,%20and%20Technical%20Advancement&amp;volume=14&amp;issue=2&amp;publication_year=2025&amp;pages=314&amp;pmid=39860320&amp;doi=10.3390/jcm14020314&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0035">
<span class="label">35.</span><cite>Wang Q, Xia D, Bai W, et al. 
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J Hepatol. 2019;70(5):893–903. doi: 10.1016/j.jhep.2019.01.013
</cite> [<a href="https://doi.org/10.1016/j.jhep.2019.01.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30660709/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=Development%20of%20a%20prognostic%20score%20for%20recommended%20TACE%20candidates%20with%20hepatocellular%20carcinoma:%20a%20multicentre%20observational%20study&amp;volume=70&amp;issue=5&amp;publication_year=2019&amp;pages=893-903&amp;pmid=30660709&amp;doi=10.1016/j.jhep.2019.01.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0036">
<span class="label">36.</span><cite>Raoul J-L, Gilabert M, Piana G.. 
How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer. 2014;3(2):119–124. doi: 10.1159/000343867
</cite> [<a href="https://doi.org/10.1159/000343867" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4057788/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24945002/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Cancer&amp;title=How%20to%20define%20transarterial%20chemoembolization%20failure%20or%20refractoriness:%20a%20European%20perspective&amp;volume=3&amp;issue=2&amp;publication_year=2014&amp;pages=119-124&amp;pmid=24945002&amp;doi=10.1159/000343867&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0037">
<span class="label">37.</span><cite>Kassab I, Singal AG, Ali A, et al. 
Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization. Hepatol Commun. 2023;7(4):e0091. doi: 10.1097/HC9.0000000000000091
</cite> [<a href="https://doi.org/10.1097/HC9.0000000000000091" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10043575/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36972387/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatol%20Commun&amp;title=Stage%20migration%20as%20a%20surrogate%20of%20survival%20in%20hepatocellular%20carcinoma%20treated%20with%20transarterial%20chemoembolization&amp;volume=7&amp;issue=4&amp;publication_year=2023&amp;pages=e0091&amp;pmid=36972387&amp;doi=10.1097/HC9.0000000000000091&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0038">
<span class="label">38.</span><cite>Benkö T, König J, Theysohn JM, et al. 
Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?
Eur J Med Res. 2022;27(1):74. doi: 10.1186/s40001-022-00708-w
</cite> [<a href="https://doi.org/10.1186/s40001-022-00708-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9134704/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35619164/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Med%20Res&amp;title=Bridging%20treatment%20prior%20to%20liver%20transplantation%20for%20hepatocellular%20carcinoma:%20radioembolization%20or%20transarterial%20chemoembolization?&amp;volume=27&amp;issue=1&amp;publication_year=2022&amp;pages=74&amp;pmid=35619164&amp;doi=10.1186/s40001-022-00708-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0039">
<span class="label">39.</span><cite>Sapisochin G, Barry A, Doherty M, et al. 
Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–99. doi: 10.1016/j.jhep.2017.02.022
</cite> [<a href="https://doi.org/10.1016/j.jhep.2017.02.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28257902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=Stereotactic%20body%20radiotherapy%20vs.%20TACE%20or%20RFA%20as%20a%20bridge%20to%20transplant%20in%20patients%20with%20hepatocellular%20carcinoma.%20An%20intention-to-treat%20analysis&amp;volume=67&amp;issue=1&amp;publication_year=2017&amp;pages=92-99&amp;pmid=28257902&amp;doi=10.1016/j.jhep.2017.02.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0040">
<span class="label">40.</span><cite>Sneiders D, Boteon AP, Lerut J, et al. 
Transarterial chemoembolization of hepatocellular carcinoma before liver transplantation and risk of post-transplant vascular complications: A multicentre observational cohort and propensity score-matched analysis. Br J Surg. 2021;108(11):1323–1331. doi: 10.1093/bjs/znab268
</cite> [<a href="https://doi.org/10.1093/bjs/znab268" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34611694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Surg&amp;title=Transarterial%20chemoembolization%20of%20hepatocellular%20carcinoma%20before%20liver%20transplantation%20and%20risk%20of%20post-transplant%20vascular%20complications:%20A%20multicentre%20observational%20cohort%20and%20propensity%20score-matched%20analysis&amp;volume=108&amp;issue=11&amp;publication_year=2021&amp;pages=1323-1331&amp;pmid=34611694&amp;doi=10.1093/bjs/znab268&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0041">
<span class="label">41.</span><cite>**Salem R, Johnson GE, Kim E, et al. 
Yttrium‐90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342–2352. doi: 10.1002/hep.31819
</cite> [<a href="https://doi.org/10.1002/hep.31819" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8596669/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33739462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Yttrium%E2%80%9090%20radioembolization%20for%20the%20treatment%20of%20solitary,%20unresectable%20HCC:%20the%20LEGACY%20study&amp;volume=74&amp;issue=5&amp;publication_year=2021&amp;pages=2342-2352&amp;pmid=33739462&amp;doi=10.1002/hep.31819&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>This study shows the potential benefits of high dose dosimetry using Y90 therapy for the treatment of a solitary hepatocellular carcinoma.</cite>
</li>
<li id="CIT0042">
<span class="label">42.</span><cite>Garin E, Tselikas L, Guiu B, et al. 
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. doi: 10.1016/S2468-1253(20)30290-9
</cite> [<a href="https://doi.org/10.1016/S2468-1253(20)30290-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33166497/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Gastroenterol%20Hepatol&amp;title=Personalised%20versus%20standard%20dosimetry%20approach%20of%20selective%20internal%20radiation%20therapy%20in%20patients%20with%20locally%20advanced%20hepatocellular%20carcinoma%20(DOSISPHERE-01):%20a%20randomised,%20multicentre,%20open-label%20phase%202%20trial&amp;volume=6&amp;issue=1&amp;publication_year=2021&amp;pages=17-29&amp;pmid=33166497&amp;doi=10.1016/S2468-1253(20)30290-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0043">
<span class="label">43.</span><cite>Brown AM, Kassab I, Massani M, et al. 
TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis. Cancer Med. 2023;12(3):2590–2599. doi: 10.1002/cam4.5125
</cite> [<a href="https://doi.org/10.1002/cam4.5125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9939158/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35943116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Med&amp;title=TACE%20versus%20TARE%20for%20patients%20with%20hepatocellular%20carcinoma:%20overall%20and%20individual%20patient%20level%20meta%20analysis&amp;volume=12&amp;issue=3&amp;publication_year=2023&amp;pages=2590-2599&amp;pmid=35943116&amp;doi=10.1002/cam4.5125&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0044">
<span class="label">44.</span><cite>Dhondt E, Lambert B, Hermie L, et al. 
90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699–710. doi: 10.1148/radiol.211806
</cite> [<a href="https://doi.org/10.1148/radiol.211806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35258371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiology&amp;title=90Y%20radioembolization%20versus%20drug-eluting%20bead%20chemoembolization%20for%20unresectable%20hepatocellular%20carcinoma:%20results%20from%20the%20TRACE%20phase%20II%20randomized%20controlled%20trial&amp;volume=303&amp;issue=3&amp;publication_year=2022&amp;pages=699-710&amp;pmid=35258371&amp;doi=10.1148/radiol.211806&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0045">
<span class="label">45.</span><cite>Parikh ND, Cuneo K, Mendiratta‐Lala M.. 
Radiation therapies for the treatment of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2021;17(5):341–346. doi: 10.1002/cld.1060
</cite> [<a href="https://doi.org/10.1002/cld.1060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8177829/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34136139/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Liver%20Dis%20(Hoboken)&amp;title=Radiation%20therapies%20for%20the%20treatment%20of%20hepatocellular%20carcinoma&amp;volume=17&amp;issue=5&amp;publication_year=2021&amp;pages=341-346&amp;pmid=34136139&amp;doi=10.1002/cld.1060&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0046">
<span class="label">46.</span><cite>Jang WI, Kim M-S, Bae SH, et al. 
High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol. 2013;8(1):1–12. doi: 10.1186/1748-717X-8-250
</cite> [<a href="https://doi.org/10.1186/1748-717X-8-250" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4231524/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24160944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiat%20Oncol&amp;title=High-dose%20stereotactic%20body%20radiotherapy%20correlates%20increased%20local%20control%20and%20overall%20survival%20in%20patients%20with%20inoperable%20hepatocellular%20carcinoma&amp;volume=8&amp;issue=1&amp;publication_year=2013&amp;pages=1-12&amp;pmid=24160944&amp;doi=10.1186/1748-717X-8-250&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0047">
<span class="label">47.</span><cite>Feng M, Suresh K, Schipper MJ, et al. 
Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):40–47. doi: 10.1001/jamaoncol.2017.2303
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2017.2303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5766368/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28796864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Individualized%20adaptive%20stereotactic%20body%20radiotherapy%20for%20liver%20tumors%20in%20patients%20at%20high%20risk%20for%20liver%20damage:%20a%20phase%202%20clinical%20trial&amp;volume=4&amp;issue=1&amp;publication_year=2018&amp;pages=40-47&amp;pmid=28796864&amp;doi=10.1001/jamaoncol.2017.2303&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0048">
<span class="label">48.</span><cite>Sapir E, Tao Y, Schipper MJ, et al. 
Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(1):122–130. doi: 10.1016/j.ijrobp.2017.09.001
</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2017.09.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5818982/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29066120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Radiat%20Oncol%20Biol%20Phys&amp;title=Stereotactic%20body%20radiation%20therapy%20as%20an%20alternative%20to%20transarterial%20chemoembolization%20for%20hepatocellular%20carcinoma&amp;volume=100&amp;issue=1&amp;publication_year=2018&amp;pages=122-130&amp;pmid=29066120&amp;doi=10.1016/j.ijrobp.2017.09.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0049">
<span class="label">49.</span><cite>Wahl DR, Stenmark MH, Tao Y, et al. 
Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–459. doi: 10.1200/JCO.2015.61.4925
</cite> [<a href="https://doi.org/10.1200/JCO.2015.61.4925" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4872011/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26628466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Outcomes%20after%20stereotactic%20body%20radiotherapy%20or%20radiofrequency%20ablation%20for%20hepatocellular%20carcinoma&amp;volume=34&amp;issue=5&amp;publication_year=2016&amp;pages=452-459&amp;pmid=26628466&amp;doi=10.1200/JCO.2015.61.4925&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0050">
<span class="label">50.</span><cite>**Xi M, Yang Z, Hu L, et al. 
Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: A randomized, open-label, controlled trial. J Clin Oncol. 2025;43(9):1073–1082. doi: 10.1200/JCO-24-01532
</cite> [<a href="https://doi.org/10.1200/JCO-24-01532" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39693584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Radiofrequency%20ablation%20versus%20stereotactic%20body%20radiotherapy%20for%20recurrent%20small%20hepatocellular%20carcinoma:%20A%20randomized,%20open-label,%20controlled%20trial&amp;volume=43&amp;issue=9&amp;publication_year=2025&amp;pages=1073-1082&amp;pmid=39693584&amp;doi=10.1200/JCO-24-01532&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>A recent randomized study showing the benefits of SBRT for local tumor control when compared to RFA.</cite>
</li>
<li id="CIT0051">
<span class="label">51.</span><cite>Baumann BC, Wei J, Plastaras JP, et al. 
Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: high rates of local control with low toxicity. Am J Clin Oncol. 2018;41(11):1118–1124. doi: 10.1097/COC.0000000000000435
</cite> [<a href="https://doi.org/10.1097/COC.0000000000000435" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29553972/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Clin%20Oncol&amp;title=Stereotactic%20body%20radiation%20therapy%20(SBRT)%20for%20hepatocellular%20carcinoma:%20high%20rates%20of%20local%20control%20with%20low%20toxicity&amp;volume=41&amp;issue=11&amp;publication_year=2018&amp;pages=1118-1124&amp;pmid=29553972&amp;doi=10.1097/COC.0000000000000435&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0052">
<span class="label">52.</span><cite>Velec M, Haddad CR, Craig T, et al. 
Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;97(5):939–946. doi: 10.1016/j.ijrobp.2017.01.221
</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2017.01.221" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28333016/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Radiat%20Oncol%20Biol%20Phys&amp;title=Predictors%20of%20liver%20toxicity%20following%20stereotactic%20body%20radiation%20therapy%20for%20hepatocellular%20carcinoma&amp;volume=97&amp;issue=5&amp;publication_year=2017&amp;pages=939-946&amp;pmid=28333016&amp;doi=10.1016/j.ijrobp.2017.01.221&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0053">
<span class="label">53.</span><cite>Fleming C, Sittenfeld S, Kim A, et al. 
Downstaging of hepatocellular carcinoma outside Milan criteria using SBRT. Int J Radiat Oncol Biol Phys. 2019;105(1):E219. doi: 10.1016/j.ijrobp.2019.06.1969</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2019.06.1969" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Radiat%20Oncol%20Biol%20Phys&amp;title=Downstaging%20of%20hepatocellular%20carcinoma%20outside%20Milan%20criteria%20using%20SBRT&amp;volume=105&amp;issue=1&amp;publication_year=2019&amp;pages=E219&amp;doi=10.1016/j.ijrobp.2019.06.1969&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0054">
<span class="label">54.</span><cite>Groeschl RT, Pilgrim CH, Hanna EM, et al. 
Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195–1200. doi: 10.1097/SLA.0000000000000234
</cite> [<a href="https://doi.org/10.1097/SLA.0000000000000234" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24096760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg&amp;title=Microwave%20ablation%20for%20hepatic%20malignancies:%20a%20multiinstitutional%20analysis&amp;volume=259&amp;issue=6&amp;publication_year=2014&amp;pages=1195-1200&amp;pmid=24096760&amp;doi=10.1097/SLA.0000000000000234&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0055">
<span class="label">55.</span><cite>Mendiratta-Lala M, Wiggermann P, Pech M, et al. 
The# HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors. Radiology. 2024;312(3):e233051. doi: 10.1148/radiol.233051
</cite> [<a href="https://doi.org/10.1148/radiol.233051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11427859/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39225612/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiology&amp;title=The#%20HOPE4LIVER%20single-arm%20pivotal%20trial%20for%20histotripsy%20of%20primary%20and%20metastatic%20liver%20tumors&amp;volume=312&amp;issue=3&amp;publication_year=2024&amp;pages=e233051&amp;pmid=39225612&amp;doi=10.1148/radiol.233051&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0056">
<span class="label">56.</span><cite>Takayama T, Hasegawa K, Izumi N, et al. 
Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF trial). Liver Cancer. 2022;11(3):209–218. doi: 10.1159/000521665
</cite> [<a href="https://doi.org/10.1159/000521665" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9218617/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35949295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Cancer&amp;title=Surgery%20versus%20radiofrequency%20ablation%20for%20small%20hepatocellular%20carcinoma:%20a%20randomized%20controlled%20trial%20(SURF%20trial)&amp;volume=11&amp;issue=3&amp;publication_year=2022&amp;pages=209-218&amp;pmid=35949295&amp;doi=10.1159/000521665&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0057">
<span class="label">57.</span><cite>Lee MW, Raman SS, Asvadi NH, et al. 
Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10‐year intention‐to‐treat analysis. Hepatology. 2017;65(6):1979–1990. doi: 10.1002/hep.29098
</cite> [<a href="https://doi.org/10.1002/hep.29098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28170115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Radiofrequency%20ablation%20of%20hepatocellular%20carcinoma%20as%20bridge%20therapy%20to%20liver%20transplantation:%20A%2010%E2%80%90year%20intention%E2%80%90to%E2%80%90treat%20analysis&amp;volume=65&amp;issue=6&amp;publication_year=2017&amp;pages=1979-1990&amp;pmid=28170115&amp;doi=10.1002/hep.29098&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0058">
<span class="label">58.</span><cite>DuBay DA, Sandroussi C, Kachura JR, et al. 
Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford). 2011;13(1):24–32. doi: 10.1111/j.1477-2574.2010.00228.x
</cite> [<a href="https://doi.org/10.1111/j.1477-2574.2010.00228.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3019538/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21159100/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=HPB%20(Oxford)&amp;title=Radiofrequency%20ablation%20of%20hepatocellular%20carcinoma%20as%20a%20bridge%20to%20liver%20transplantation&amp;volume=13&amp;issue=1&amp;publication_year=2011&amp;pages=24-32&amp;pmid=21159100&amp;doi=10.1111/j.1477-2574.2010.00228.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0059">
<span class="label">59.</span><cite>Li M, Bhoori S, Mehta N, et al. 
Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation. J Hepatol. 2024;81(4):743–755. doi: 10.1016/j.jhep.2024.05.037
</cite> [<a href="https://doi.org/10.1016/j.jhep.2024.05.037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38848767/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=Immunotherapy%20for%20hepatocellular%20carcinoma:%20the%20next%20evolution%20in%20expanding%20access%20to%20liver%20transplantation&amp;volume=81&amp;issue=4&amp;publication_year=2024&amp;pages=743-755&amp;pmid=38848767&amp;doi=10.1016/j.jhep.2024.05.037&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0060">
<span class="label">60.</span><cite>**D’Alessio A, Stefanini B, Blanter J, et al. 
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024;25(11):1465–1475. doi: 10.1016/S1470-2045(24)00457-1
</cite> [<a href="https://doi.org/10.1016/S1470-2045(24)00457-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12040480/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39437804/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Pathological%20response%20following%20neoadjuvant%20immune%20checkpoint%20inhibitors%20in%20patients%20with%20hepatocellular%20carcinoma:%20a%20cross-trial,%20patient-level%20analysis&amp;volume=25&amp;issue=11&amp;publication_year=2024&amp;pages=1465-1475&amp;pmid=39437804&amp;doi=10.1016/S1470-2045(24)00457-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>The benefits of neoadjuvant immune checkpoint inhibitor-based systemic therapy on pathological response and post resection recurrence are demonstrated in this paper.</cite>
</li>
<li id="CIT0061">
<span class="label">61.</span><cite>Schnickel GT, Fabbri K, Hosseini M, et al. 
Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. Am J Transplant. 2022;22(6):1699–1704. doi: 10.1111/ajt.16965
</cite> [<a href="https://doi.org/10.1111/ajt.16965" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9177653/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35080128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=Liver%20transplantation%20for%20hepatocellular%20carcinoma%20following%20checkpoint%20inhibitor%20therapy%20with%20nivolumab&amp;volume=22&amp;issue=6&amp;publication_year=2022&amp;pages=1699-1704&amp;pmid=35080128&amp;doi=10.1111/ajt.16965&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0062">
<span class="label">62.</span><cite>Nordness MF, Hamel S, Godfrey CM, et al. 
Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
Am J Transplant. 2020;20(3):879–883. doi: 10.1111/ajt.15617
</cite> [<a href="https://doi.org/10.1111/ajt.15617" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10176099/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31550417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=Fatal%20hepatic%20necrosis%20after%20nivolumab%20as%20a%20bridge%20to%20liver%20transplant%20for%20HCC:%20Are%20checkpoint%20inhibitors%20safe%20for%20the%20pretransplant%20patient?&amp;volume=20&amp;issue=3&amp;publication_year=2020&amp;pages=879-883&amp;pmid=31550417&amp;doi=10.1111/ajt.15617&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0063">
<span class="label">63.</span><cite>Tabrizian P, Florman SS, Schwartz ME.. 
PD-1 inhibitor as bridge therapy to liver transplantation?
Am J Transplant. 2021;21(5):1979–1980. doi: 10.1111/ajt.16448
</cite> [<a href="https://doi.org/10.1111/ajt.16448" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33316117/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=PD-1%20inhibitor%20as%20bridge%20therapy%20to%20liver%20transplantation?&amp;volume=21&amp;issue=5&amp;publication_year=2021&amp;pages=1979-1980&amp;pmid=33316117&amp;doi=10.1111/ajt.16448&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0064">
<span class="label">64.</span><cite>Rezaee-Zavareh MS, Yeo YH, Wang T.. 
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 2025;82(1):e64–e66. doi: 10.1016/j.jhep.2024.09.019
</cite> [<a href="https://doi.org/10.1016/j.jhep.2024.09.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11655254/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38996924/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=Impact%20of%20pre-transplant%20immune%20checkpoint%20inhibitor%20use%20on%20post-transplant%20outcomes%20in%20HCC:%20A%20systematic%20review%20and%20individual%20patient%20data%20meta-analysis&amp;volume=82&amp;issue=1&amp;publication_year=2025&amp;pages=e64-e66&amp;pmid=38996924&amp;doi=10.1016/j.jhep.2024.09.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0065">
<span class="label">65.</span><cite>*Sangro B, Kudo M, Erinjeri JP, et al. 
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405(10474):216–232. doi: 10.1016/S0140-6736(24)02551-0
</cite> [<a href="https://doi.org/10.1016/S0140-6736(24)02551-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12282661/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39798579/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Durvalumab%20with%20or%20without%20bevacizumab%20with%20transarterial%20chemoembolisation%20in%20hepatocellular%20carcinoma%20(EMERALD-1):%20a%20multiregional,%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20study&amp;volume=405&amp;issue=10474&amp;publication_year=2025&amp;pages=216-232&amp;pmid=39798579&amp;doi=10.1016/S0140-6736(24)02551-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>This trial demonstrates the benefits of durvalumab and bevacizumab when combined with TACE with improvement in progression free survival.</cite>
</li>
<li id="CIT0066">
<span class="label">66.</span><cite>Kudo M, Ren Z, Guo Y, et al. 
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The. Lancet. 2025;405(10474):203–215. doi: 10.1016/S0140-6736(24)02575-3
</cite> [<a href="https://doi.org/10.1016/S0140-6736(24)02575-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39798578/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Transarterial%20chemoembolisation%20combined%20with%20lenvatinib%20plus%20pembrolizumab%20versus%20dual%20placebo%20for%20unresectable,%20non-metastatic%20hepatocellular%20carcinoma%20(LEAP-012):%20a%20multicentre,%20randomised,%20double-blind,%20phase%203%20study.%20The&amp;volume=405&amp;issue=10474&amp;publication_year=2025&amp;pages=203-215&amp;pmid=39798578&amp;doi=10.1016/S0140-6736(24)02575-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]; <cite>This trial demonstrates the benefits of lenvatiib and pembrolizumab when combined with TACE with improvement in progression free survival.</cite>
</li>
<li id="CIT0067">
<span class="label">67.</span><cite>Lyu N, Wang X, Li JB, et al. 
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–480. doi: 10.1200/JCO.21.01963
</cite> [<a href="https://doi.org/10.1200/JCO.21.01963" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34905388/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Arterial%20Chemotherapy%20of%20Oxaliplatin%20Plus%20Fluorouracil%20Versus%20Sorafenib%20in%20Advanced%20Hepatocellular%20Carcinoma:%20A%20Biomolecular%20Exploratory,%20Randomized,%20Phase%20III%20Trial%20(FOHAIC-1)&amp;volume=40&amp;issue=5&amp;publication_year=2022&amp;pages=468-480&amp;pmid=34905388&amp;doi=10.1200/JCO.21.01963&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0068">
<span class="label">68.</span><cite>Hill AL, Cullinan DR, Ahmed O, et al. 
Liver Transplantation After Hepatic Artery Infusion Pump Therapy: Single-Center Experience and Technical Considerations. Ann Surg Oncol. 2023;30(8):4775–4780. doi: 10.1245/s10434-023-13652-8
</cite> [<a href="https://doi.org/10.1245/s10434-023-13652-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37210451/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg%20Oncol&amp;title=Liver%20Transplantation%20After%20Hepatic%20Artery%20Infusion%20Pump%20Therapy:%20Single-Center%20Experience%20and%20Technical%20Considerations&amp;volume=30&amp;issue=8&amp;publication_year=2023&amp;pages=4775-4780&amp;pmid=37210451&amp;doi=10.1245/s10434-023-13652-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CIT0069">
<span class="label">69.</span><cite>Parikh ND, Pillai A.. 
Recent advances in hepatocellular carcinoma treatment. Clin Gastroenterol Hepatol. 2021;19(10):2020–2024. doi: 10.1016/j.cgh.2021.05.045
</cite> [<a href="https://doi.org/10.1016/j.cgh.2021.05.045" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34116048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&amp;title=Recent%20advances%20in%20hepatocellular%20carcinoma%20treatment&amp;volume=19&amp;issue=10&amp;publication_year=2021&amp;pages=2020-2024&amp;pmid=34116048&amp;doi=10.1016/j.cgh.2021.05.045&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Hepatic Oncology are provided here courtesy of <strong>Taylor & Francis</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1080/20450923.2025.2549676"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/IHEP_12_2549676.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (909.2 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12377145/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12377145/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12377145%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377145/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12377145/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12377145/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40847915/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12377145/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40847915/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12377145/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12377145/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="sTiQnvvpjlIwWvWOO5UMBxZQAoKFSarmCiMWWPVFUbyWee0Px90i1SXOFdBwmlZa">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-574fdcc6.js"></script>
    
    

    </body>
</html>
